COCH Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
51.0K
+30.8%
39.0K
-48.0%
75.0K
+78.6%
42.0K
-46.2%
78.0K
Cost of Revenue
278.0K
-11.2%
313.0K
+48.3%
211.0K
+3.9%
203.0K
-13.2%
234.0K
Gross Profit
-227000
+17.2%
-274000
-101.5%
-136000
+15.5%
-161000
-3.2%
-156000
Operating Expenses
5.3M
-6.0%
5.7M
-9.0%
6.2M
+12.7%
5.5M
+12.9%
4.9M
R&D
3.1M
-14.0%
3.6M
-20.0%
4.6M
+68.6%
2.7M
+8.7%
2.5M
SG&A
2.2M
+8.2%
2.0M
+20.5%
1.7M
-40.4%
2.8M
+17.2%
2.4M
Operating Income
-5569000
+6.5%
-5959000
+6.7%
-6385000
-11.9%
-5708000
-12.6%
-5070000
EBITDA
-5495000
+6.6%
-5886000
+6.6%
-6305000
-11.9%
-5632000
-13.0%
-4985000
Net Income
-5982000
-37.5%
-4351000
+33.9%
-6586000
-1.6%
-6482000
-13.9%
-5690000
EPS (Basic)
$-0.07
+12.5%
$-0.08
+70.4%
$-0.27
+22.9%
$-0.35
-9.4%
$-0.32
EPS (Diluted)
$-0.07
+12.5%
$-0.08
+70.4%
$-0.27
+22.9%
$-0.35
-9.4%
$-0.32
Shares (Diluted)
104.0M
+50.9%
68.9M
+142.1%
28.5M
+30.3%
21.9M
+2.2%
21.4M
Envoy Medical (COCH) โ€” Financials